Fortis Therapeutics is focused on developing new antibody drug conjugate therapies for late-stage metastatic castrate-resistant prostate cancer and multiple myeloma.
Fortis Therapeutics was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Dr. Bin Liu, and is a part of COI Pharmaceuticals portfolio.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
In Sep 2016, Fortis Therapeutics raised $18 Mn in Series A financing. The investment was led by Avalon Ventures and was joined by Bregua Corporation, Lilly Asia Ventures, Osage University Partners, and Vivo Capital.
Recover your password.
A password will be e-mailed to you.